mRNA Vaccine

Disclaimer: Copyright infringement not intended.

Context

• The Drugs Controller General of India (DCGI) on Tuesday approved India's first indigenously developed mRNA vaccine against COVID-19manufactured by Gennova Biopharmaceuticals for restricted emergency use for those aged 18 years and above.

mRNA vaccines

• The mRNA vaccines do not use the conventional model to produce immune response.
• Instead, mRNA vaccine carries the molecular instructions to make the protein in the body through a synthetic RNA of the virus.
• The host body uses this to produce the viral protein that is recognized and thereby making the body mount an immune response against the disease.
• mRNA-based vaccines are scientifically the ideal choice to address a pandemic because of their rapid developmental timeline.
• The mRNA vaccine is considered safe as is non-infectious, non-integrating in nature, and degraded by standard cellular mechanisms.
• They are expected to be highly efficacious because of their inherent capability of being translatable into the protein structure inside the cell cytoplasm.
• Additionally, mRNA vaccines are fully synthetic and do not require a host for growth, e.g., eggs or bacteria. Therefore, they can be quickly manufactured in an inexpensive manner under cGMP conditions to ensure their "availability" and "accessibility" for mass vaccination on a sustainable basis.

https://www.thehindu.com/news/national/dcgi-nod-restricted-emergency-use-indigenous-mrna-covid-jab-18-years-above/article65577382.ece